DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
L-Leucine is an investigational drug.
There have been 26 clinical trials for L-Leucine. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2001.
The most common disease conditions in clinical trials are Neuroblastoma, Ganglioneuroblastoma, and Diabetes Mellitus. The leading clinical trial sponsors are National Cancer Institute (NCI), Roswell Park Cancer Institute, and IntraBio Inc.
Recent Clinical Trials for L-Leucine
|Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma||National Cancer Institute (NCI)||Phase 2|
|Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma||Children's Oncology Group||Phase 2|
|Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors||National Cancer Institute (NCI)||Phase 1|